ML385: Selective NRF2 Inhibitor for Cancer Research and Oxidative Stress Modulation

Executive Summary: ML385 (CAS 846557-71-9) is a well-characterized selective inhibitor of the transcription factor NRF2, with an IC50 of 1.9 μM in biochemical assays (APExBIO product documentation). NRF2 regulates oxidative stress responses and multidrug resistance in cancer models, notably in non-small cell lung cancer (NSCLC) (Zhou et al., 2024). ML385 downregulates NRF2-dependent gene expression in a dose- and time-dependent manner in A549 NSCLC cells. In mouse models, ML385 reduces tumor growth and enhances carboplatin efficacy. It is insoluble in ethanol and water but dissolves at ≥13.33 mg/mL in DMSO, and must be stored at -20°C to retain stability (APExBIO).

Biological Rationale

NRF2 (nuclear factor erythroid 2-related factor 2) is a master transcriptional regulator of cellular antioxidant defenses, detoxification enzymes, and multidrug transporters (Zhou et al., 2024). Its overactivation is implicated in cancer cell survival, proliferation, and resistance to chemotherapy—especially in non-small cell lung cancer (NSCLC). Targeting NRF2 allows researchers to investigate how redox balance, ferroptosis, and resistance mechanisms operate in cancer and liver disease models. ML385 enables selective and reversible inhibition of NRF2-mediated transcription, making it a critical tool for dissecting antioxidant response regulation. This article extends the protocol-focused guidance found in "ML385: Selective NRF2 Inhibitor for Cancer & Oxidative Stress Research" by providing mechanistic and benchmarking data for advanced studies.

Mechanism of Action of ML385

ML385 binds directly to the Neh1 domain of NRF2, thereby blocking the interaction of NRF2 with its DNA antioxidant response element (ARE) binding sites (APExBIO). This inhibition prevents the transcriptional activation of NRF2 target genes, including those involved in glutathione biosynthesis, detoxification, and ferroptosis resistance. The effect is dose- and time-dependent, with measurable reduction in NRF2 activity and downstream gene expression within hours in cell-based assays. ML385 does not inhibit related transcription factors at comparable concentrations, confirming its selectivity. These findings clarify the broader overviews in "ML385 (SKU B8300): Precision NRF2 Inhibition for Cancer and Redox Studies" by detailing direct molecular interactions.

Evidence & Benchmarks

• ML385 exhibits an IC50 of 1.9 μM for NRF2 inhibition in cell-free biochemical assays (APExBIO).
• In A549 NSCLC cell lines, ML385 reduces NRF2-driven gene expression and lowers glutathione S-transferase levels in a concentration- and time-dependent fashion (Zhou et al., 2024).
• In vivo, ML385 (100 mg/kg/day, intraperitoneal) reduces liver oxidative stress and improves alcoholic liver injury in rodent models when combined with other modulators (Zhou et al., 2024).
• ML385 enhances the efficacy of carboplatin in NSCLC mouse xenografts, resulting in greater tumor regression compared to either agent alone (APExBIO).
• ML385 is insoluble in ethanol and water, but soluble at ≥13.33 mg/mL in DMSO, supporting high-concentration stock solutions for in vitro and in vivo use (APExBIO).

This section updates the clinical and translational focus of "ML385: A Selective NRF2 Inhibitor Transforming Cancer and Oxidative Stress Research" by providing new quantitative benchmarks and solubility parameters.

Applications, Limits & Misconceptions

ML385 is widely used for:

• Mapping NRF2 signaling in cancer, liver, and neurodegeneration models
• Quantifying effects on oxidative stress, ferroptosis, and detoxification gene expression
• Testing combination therapies to overcome drug resistance in cancer cells
• Dissecting NRF2's role in inflammatory and metabolic responses

Common Pitfalls or Misconceptions

• ML385 is not effective in models where NRF2 is genetically deleted or mutated at the Neh1 domain.
• It does not inhibit other transcription factors such as NF-κB or AP-1 at standard concentrations; selectivity must be confirmed in each system.
• ML385 is ineffective if prepared in water or ethanol due to insolubility; only DMSO stocks are reliable.
• Long-term storage of ML385 solutions (>1 week at -20°C) can lead to degradation and reduced efficacy.
• ML385 effects are reversible; continuous exposure is required for sustained NRF2 inhibition in cell culture.

Workflow Integration & Parameters

For in vitro studies, ML385 is typically used at 1–10 μM in DMSO (<1% final solvent). For in vivo studies, doses of 100 mg/kg/day (intraperitoneal injection) have been validated in rodent models of liver injury and cancer (Zhou et al., 2024). The compound should be stored as a dry powder at -20°C and freshly dissolved in DMSO before use. Avoid repeated freeze-thaw cycles. When designing combination therapy experiments, ML385 can be administered prior to or alongside chemotherapeutic agents such as carboplatin to investigate synergistic effects on tumor regression. Always include NRF2 expression and target gene readouts to confirm pathway inhibition. For troubleshooting and optimization, see the detailed protocols in this stepwise application guide.

Conclusion & Outlook

ML385, supplied by APExBIO, is a validated, selective NRF2 inhibitor with robust applications in cancer and oxidative stress research. Its well-characterized mechanism, reproducible efficacy, and defined solubility make it a standard for dissecting NRF2-dependent biology. Continued benchmarking in diverse models will further clarify its use in combination therapies and disease-specific NRF2 targeting. For additional application notes and scenario-driven guidance, consult the referenced literature and product documentation (ML385 product page).